Time filter

Source Type

To investigate the effect of metoprolol succinate sustained-release tablets on cardiac function, serum vascular endothelial growth factor (VEGF) and C-reactive protein (CRP) in elderly hypertensive patients and its relation with pulse pressure (PP). A total of 330 elderly hypertensive patients with chronic heart failure receiving basic therapy were included. Before initiation and 3 months after the maximal tolerated dose of metoprolol succinate sustained-release tablets, the parameters of blood pressure, clinical features, radionuclide ventriculographic and laboratory findings of the patients were analyzed. As the PP was elevated, the serum levels of VEGF, hs-CRP and BNP increased and the cardiac systolic and diastolic functions decreased. In patients with PP of 59-68 mmHg and > 68 mmHg, 3 months of treatment with the tablets caused significantly increased LVEF by (3.32 ± 2.35)% and (4.12 ± 3.05)% and LVPER by 0.37 ± 0.26 and 0.53 ± 0.37, respectively; PP were decreased by 8.2 ± 3.1 mmHg and 9.4 ± 4.3 mmHg and VEGF by 18.39 ± 8.43 pg/ml and 26.79 ± 14.32 pg/ml, respectively. The treatment also resulted in lowered hs-CRP and BNP in these patients by 0.26 ± 0.13 mg/L and 0.33 ± 0.16 mg/L and by 140.36 ± 68.62 ng/L and 155.39 ± 73.58 ng/L, respectively. Obvious elevation of PP is associated with a better response to metoprolol succinate sustained-release tablets in elderly hypertensive patients with chronic heart failure, and 3 months of treatment with the tablets can significantly improve the cardiac function and lower the levels of VEGF, hs-CRP and BNP in these patients. Source

Li L.,CAS Technical Institute of Physics and Chemistry | Guan Y.,Capital Medical University | Liu H.,CAS Technical Institute of Physics and Chemistry | Hao N.,CAS Technical Institute of Physics and Chemistry | And 11 more authors.
ACS Nano | Year: 2011

Low targeting efficiency is one of the biggest limitations for nanoparticulate drug delivery system-based cancer therapy. In this study, an efficient approach for tumor-targeted drug delivery was developed with mesenchymal stem cells as the targeting vehicle and a silica nanorattle as the drug carrier. A silica nanorattle-doxorubicin drug delivery system was efficiently anchored to mesenchymal stem cells (MSCs) by specific antibody-antigen recognitions at the cytomembrane interface without any cell preconditioning. Up to 1500 nanoparticles were uploaded to each MSC cell with high cell viability and tumor-tropic ability. The intracellular retention time of the silica nanorattle was no less than 48 h, which is sufficient for cell-directed tumor-tropic delivery. In vivo experiments proved that the burdened MSCs can track down the U251 glioma tumor cells more efficiently and deliver doxorubicin with wider distribution and longer retention lifetime in tumor tissues compared with free DOX and silica nanorattle-encapsulated DOX. The increased and prolonged DOX intratumoral distribution further contributed to significantly enhanced tumor-cell apoptosis. This strategy has potential to be developed as a robust and generalizable method for targeted tumor therapy with high efficiency and low systematic toxicity. © 2011 American Chemical Society. Source

Lin Z.P.,Sun Yat sen Cardiovascular Hospital | Dong M.,Shenzhen University | Liu J.,Shenzhen University
European Review for Medical and Pharmacological Sciences | Year: 2013

AIM: This study was designed to determine the effect of bisoprolol on endothelial function of brachial artery and the myocardium survival in hypertensive patients with stable angina. PATIENTS AND METHODS: 222 subjects with hypertension who had received coronary angiography examination were involved in the study, 162 in bisoprolol therapy group (96 men, 59%) and 60 in non-bisoprolol group (39 men, 65%). In accordance with results of angiography (coronary stenosis ≥ 50%), the patients in bisoprolol group were divided into three sub-groups: (1) single-vessel coronary disease group (n=42); (2) double-vessel coronary disease group (n=44); (3) multi-vessel coronary disease group (n=39) and hypertension- only group (n=37). All the subjects were treated with conventional drugs plus bisoprolol and followed up for 12 months. Parameters of clinical features, echocardiography, radionuclide ventriculographic and laboratory findings were measured and analyzed. RESULTS: After 12 months bisoprolol treatment, the flow-mediated vasodilatation (FMD) and 99Tcm-sestamibi (99Tcm-MIBI) uptake fraction which reflects the survival of myocardium were improved markedly in bisoprolol group (all p < 0.05). Interestingly, a more significant improvement in FMD and 99Tcm-MIBI uptake fraction were observed in severe coronary disease sub-groups (double-vessel group and multi-vessel group) when compared with single-vessel sub-group (p < 0.05). CONCLUSIONS: Hypertensive subjects with stable angina might get benefit from the treatment of bisoprolol in improving endothelial function and the survival of myocardium. Source

Lin Z.P.,Sun Yat sen Cardiovascular Hospital
Nan fang yi ke da xue xue bao = Journal of Southern Medical University | Year: 2011

To evaluate the effect of rosuvastatin on the functions of the surviving myocardium and arteriosclerosis plaque in patients with ST-segment elevation after acute myocardial infarction (STEMI) and percutaneous coronary intervention (PCI). Sixty-five STEMI patients were randomized to receive 40 mg simvastatin (n=32) or 10 mg rosuvastatin (n=33) before sleep in addition to conventional medications. Before PCI and after the 12-month medications, the plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were measured, and echocardiography and (99)Tc(m)-MIBI single-photon emission computed tomography (SPECT) were performed to assess the therapeutic effects. At the end of 12 months, the patients in simvastatin group showed significantly reduced total cholesterol, LDL-C, CRP, TNF-α, and (99)Tc(m)-MIBI uptake fraction. In rosuvastatin group, these reductions were even more obvious; the intima media thickness (IMT) of the common carotid artery was reduced significantly after a 12-month rosuvastatin therapy, but almost remained unchanged after simvastatin therapy. Rosuvastatin therapy in addition to conventional medications can significantly reduce IMT and improve the functions of the surviving myocardium in patients with STEMI after PCI. Source

Qiao X.,Chongqing Zhoushan Hospital | Qiao X.,Chongqing Medical University | Xu J.,Wuhan University | Yang Q.-J.,Chongqing Zhoushan Hospital | And 5 more authors.
Oxidative Medicine and Cellular Longevity | Year: 2013

In this paper, we concluded that transient acidosis reperfusion conferred cardioprotection against myocardial ischemia reperfusion injury in isolated rat hearts through activating PI3K-Akt-eNOS pathway. © 2013 Xin Qiao et al. Source

Discover hidden collaborations